拱东医疗(605369) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 26,447.58 million, a decrease of 2.74% compared to CNY 27,191.85 million in the same period last year[6]. - Net profit attributable to shareholders decreased by 39.23% to CNY 2,741.25 million from CNY 4,510.90 million year-on-year[6]. - Basic earnings per share fell by 41.38% to CNY 0.17 per share, down from CNY 0.29 per share in the previous year[6]. - Net profit for Q1 2025 was ¥27,262,268.82, down 39.6% from ¥45,108,983.69 in Q1 2024[24]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.17, compared to ¥0.29 in Q1 2024[24]. Cash Flow and Investments - The net cash flow from operating activities decreased by 49.96% to CNY 2,055.00 million, compared to CNY 4,106.50 million in the same period last year[6]. - Net cash flow from operating activities for Q1 2025 was ¥20,549,989.34, a decrease of 50.0% from ¥41,065,035.92 in Q1 2024[27]. - The company reported a net cash outflow from investing activities of ¥19,017,455.73 in Q1 2025, compared to a net outflow of ¥24,124,466.30 in Q1 2024[28]. - The company raised ¥87,500,000.00 from financing activities in Q1 2025, compared to a net outflow of ¥1,622,484.19 in Q1 2024[28]. Assets and Liabilities - Total assets increased by 5.88% to CNY 206,613.61 million from CNY 195,134.02 million at the end of the previous year[6]. - As of March 31, 2025, the total assets of the company amounted to RMB 2,066,136,114.73, an increase from RMB 1,951,340,242.04 at the end of 2024, representing a growth of approximately 5.9%[18][20]. - The total liabilities increased to RMB 314,327,094.45 from RMB 233,788,763.79, reflecting a rise of approximately 34.4%[20]. - The company's total current assets reached RMB 990,705,786.20, up from RMB 865,266,163.55, indicating an increase of about 14.5%[19]. - The company reported a total current liability of RMB 237,855,689.24, which is an increase from RMB 182,854,626.05, representing a growth of approximately 30.1%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,909[12]. - Major shareholder施慧勇 holds 50.24% of the shares, amounting to 79,168,600 shares[12]. Other Financial Metrics - The weighted average return on equity decreased by 1.13 percentage points to 1.59% from 2.72% year-on-year[6]. - The decline in net profit was primarily due to losses from the disposal of equity interests and increased expenses related to new projects[9]. - The company reported non-recurring losses totaling CNY -7,331,520.72, significantly impacting overall profitability[8]. - The company's cash and cash equivalents stood at RMB 391,652,497.37, compared to RMB 303,188,874.77, marking a growth of around 29.1%[18]. - The accounts receivable rose to RMB 310,589,250.31 from RMB 260,245,221.85, which is an increase of approximately 19.3%[18]. - The company's non-current assets totaled RMB 1,075,430,328.53, slightly down from RMB 1,086,074,078.49, indicating a decrease of about 1.4%[19]. - The company's retained earnings increased to RMB 808,422,005.56 from RMB 781,009,541.33, showing a growth of approximately 3.5%[20]. - The total equity attributable to the owners of the parent company reached RMB 1,733,959,215.69, up from RMB 1,707,180,400.78, reflecting an increase of about 1.6%[20]. Foreign Exchange and Subsidiaries - The company experienced a foreign exchange loss of ¥149,994.35 in Q1 2025, compared to a gain of ¥490,563.19 in Q1 2024[28]. - The company did not report any net profit from subsidiaries prior to the merger in Q1 2025, consistent with Q1 2024[25].